Germany · Delayed Price · Currency is EUR Diamyd Medical AB Statistics
Total Valuation
FRA:DMN has a market cap or net worth of EUR 202.56 million. The enterprise value is 180.43 million.
| Market Cap | 202.56M |
| Enterprise Value | 180.43M |
Important Dates
The last earnings date was Wednesday, January 28, 2026.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 134.00M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +23.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.35% |
| Owned by Institutions (%) | 28.56% |
| Float | 118.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.44 |
| PS Ratio | 6,359.12 |
| PB Ratio | 9.58 |
| P/TBV Ratio | 9.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.83 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.01 |
Financial Position
The company has a current ratio of 9.50
| Current Ratio | 9.50 |
| Quick Ratio | 9.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -94.11% and return on invested capital (ROIC) is -60.98%.
| Return on Equity (ROE) | -94.11% |
| Return on Assets (ROA) | -45.01% |
| Return on Invested Capital (ROIC) | -60.98% |
| Return on Capital Employed (ROCE) | -68.36% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 777 |
| Profits Per Employee | -406,174 |
| Employee Count | 39 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.48% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.48% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 67.81 |
| Average Volume (20 Days) | 1,948 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:DMN had revenue of EUR 31,854 and -16.65 million in losses. Loss per share was -0.14.
| Revenue | 31,854 |
| Gross Profit | -304,754 |
| Operating Income | -17.26M |
| Pretax Income | -16.65M |
| Net Income | -16.65M |
| EBITDA | -16.65M |
| EBIT | -17.26M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 21.28 million in cash and n/a in debt, with a net cash position of 21.28 million.
| Cash & Cash Equivalents | 21.28M |
| Total Debt | n/a |
| Net Cash | 21.28M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 21.14M |
| Book Value Per Share | 0.15 |
| Working Capital | 19.98M |
Cash Flow
In the last 12 months, operating cash flow was -15.66 million and capital expenditures -733,088, giving a free cash flow of -16.39 million.
| Operating Cash Flow | -15.66M |
| Capital Expenditures | -733,088 |
| Free Cash Flow | -16.39M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -54,198.11% |
| Pretax Margin | -52,279.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:DMN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.27% |
| Shareholder Yield | -23.27% |
| Earnings Yield | -8.22% |
| FCF Yield | -8.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |